Back to top
more

Labcorp (LH)

(Delayed Data from NYSE)

$229.69 USD

229.69
406,015

-1.01 (-0.44%)

Updated Aug 29, 2024 04:00 PM ET

After-Market: $229.74 +0.05 (0.02%) 7:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (175 out of 251)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Is John Hancock Multifactor Mid Cap ETF (JHMM) a Strong ETF Right Now?

Smart Beta ETF report for JHMM

Veeva's (VEEV) Data Cloud to Aid PharmaEssentia's New Product

Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Commercial Cloud business.

LabCorp (LH) Upgraded to Strong Buy: What Does It Mean for the Stock?

LabCorp (LH) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Illumina (ILMN) to Develop Synthetic Genomic Data With New Pact

Illumina's (ILMN) recent collaboration will allow it to leverage the best-quality synthetic data to remove privacy bottlenecks and accelerate the development of precision medicine.

Here's Why You Should Retain Charles River (CRL) Stock for Now

Investors are optimistic about Charles River (CRL) on acquisitions of Cognate BioServices and Vigene Biosciences.

Best Growth Stocks to Buy for December 15th

CC, LH, and HCCI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 15, 2021

Here's Why You Should Retain Veeva Systems (VEEV) Stock for Now

Investors continue to be optimistic about Veeva Systems (VEEV) owing to its strong product portfolio.

Study Favors Masimo's (MASI) SedLine for Better Patient Outcome

Masimo's (MASI) SedLine is expected to aid in the early identification of patients who are at risk of developing POD.

Teleflex (TFX) Banks on Urolift Growth Amid Rising Expenses

Despite reporting softer-than-expected revenues for the third quarter, Teleflex (TFX) notes that customer preference for UroLift continues to be driven by strong clinical results.

Henry Schein's (HSIC) New Deal Broadens Medical Supplies Arm

The OMNIA Partners cooperative contract is expected to expand Henry Schein's (HSIC) offerings in the field of Point-of-Care testing, personal protective equipment and essential medical supplies.

CVS Health (CVS) Outlines Growth Strategy, Initiates 2022 View

CVS Health's (CVS) new strategy capitalizes on the considerable opportunity to make health care more convenient, personalized and affordable for consumers.

Should John Hancock Multifactor Mid Cap ETF (JHMM) Be on Your Investing Radar?

Style Box ETF report for JHMM

McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

PerkinElmer's (PKI) Latest Kit to Boost COVID-19 Surveillance

PerkinElmer's (PKI) newest addition to its SARS-CoV-2 testing portfolio is expected to aid in combating the pandemic by boosting surveillance.

Edwards (EW) States Long-Term Strategy, Provides 2022 View

Edwards Lifesciences (EW) expects to reach significant milestones in 2022 including new product launches and progress in multiple significant clinical trials.

Thermo Fisher (TMO) Gets FDA PMA for Oncomine Dx Target Test

Thermo Fisher's (TMO) Oncomine Dx Target Test will allow clinicians to use FFPE tissue samples to spot patients in the United States who may benefit from the important new therapy.

Here's Why You Should Add Chemed (CHE) to Your Portfolio Now

Investors are optimistic about Chemed (CHE) on strong third-quarter performance and raised Roto-Rooter and earnings guidance for 2021.

QIAGEN (QGEN), Denovo to Develop CDx Test for Lymphoid Cancer

QIAGEN (QGEN) will develop a diagnostic assay that can identify the Denovo Genomic Marker 1 in patients with lymphoid cancer.

BD's (BDX) Tissuemed Buyout to Boost its Surgical Solutions Arm

BD's (BDX) latest acquisition is expected to complement its currently used products and help to support minimally invasive surgeries.

Is LabCorp (LH) Outperforming Other Medical Stocks This Year?

Here is how LabCorp (LH) and Maravai LifeSciences Holdings, Inc. (MRVI) have performed compared to their sector so far this year.

PacBio (PACB)-UCLA Health Tie Up for Rare Diseases' WGS Research

PacBio's (PACB) latest research collaboration is expected to identify the causes behind rare diseases and provide more effective treatments.

Are Investors Undervaluing These Medical Stocks Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Exact Sciences' (EXAS) Oncotype DX Test Study Data Favorable

Exact Sciences' (EXAS) recent study analysis validates that the Oncotype DX test helps identify early-stage, node-positive breast cancer who can avoid chemotherapy in most women.

LH vs. WST: Which Stock Should Value Investors Buy Now?

LH vs. WST: Which Stock Is the Better Value Option?

Here's Why You Should Retain BD (BDX) Stock in Your Portfolio

Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic deals.